---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091938"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:28:54.232209+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Alan Sandler to Board; Pons and Randolph resign from Board

## Summary
- Alan Sandler, M.D., appointed to Board effective Aug 5, 2024; receives initial option for 40,400 shares vesting over 36 months.
- Jaume Pons (President/CSO) and Sophia Randolph (CMO) resign from Board to focus on executive roles; no disagreement.
- Board size decreased; now 4 of 5 directors are independent, resolving prior non-compliance with Nasdaq Rule 5605(a)(2).

## SEC filing metadata
- accession: 0000950170-24-091938
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/alxo-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091938
- JSON: https://secwatch.observer/filing/0000950170-24-091938.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091938.txt

## Key facts
- Executive change
  Sophia Randolph resigned as Director at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: Director
  source text: In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm
- Executive change
  Alan Sandler was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Director
  source text: On August 5, 2024, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D. to serve as a Class III director of the Board of Directors of the Company (the “Board”) for a term expiring at the 2026 annual meeting of stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm
- Executive change
  Jaume Pons resigned as Director at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: Director
  source text: In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.